Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

• To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
• To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC
• To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC
• To describe treatment responses, progression and survival times.
• To describe reasons for treatment discontinuation
• To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival;
• To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.

Inclusion criteria

• Patients aged 18 years or older;
• Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);
• Histologically or cytologically confirmed advanced NSCLC:

• Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
• Stage IV metastatic disease (de novo or distant relapse)
• Any NSCLC histological subtype and molecular mutation;
• Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
• Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;
• Access to patient medical chart for data collection;
• Willing and able to provide written informed consent and privacy authorization for the release of personal health information.